Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output
- PMID: 2690411
- DOI: 10.1016/0378-4274(89)90044-1
Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output
Abstract
Physiologically-based pharmacokinetic (PBPK) models may be used to predict the concentrations of parent chemical or metabolites in tissues, resulting from specified chemical exposures. An important application of PBPK modeling is in assessment of carcinogenic risks to humans, based on animal data. The parameters of a PBPK model may include metabolic parameters, blood/air and tissue/blood partition coefficients, and physiological parameters, such as organ weights and blood flow rates. Uncertainty in estimates of these parameters results in uncertainty regarding tissue concentrations and resulting risks. Data are reviewed relevant to the quantification of these uncertainties, for a PBPK model-based risk assessment for tetrachloroethylene. Probability distributions are developed to express uncertainty in model parameters, and uncertainties are propagated by a sequence of operations that simulates processes recognized as contributing to estimates of human risk. Distributions of PBPK model output and human risk estimates are used to characterize uncertainty resulting from uncertainty in model parameters.
Similar articles
-
Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE).Toxicol Lett. 1993 May;68(1-2):131-44. doi: 10.1016/0378-4274(93)90126-i. Toxicol Lett. 1993. PMID: 8516760
-
Linking indoor air and pharmacokinetic models to assess tetrachloroethylene risk.Risk Anal. 1988 Dec;8(4):509-20. doi: 10.1111/j.1539-6924.1988.tb01191.x. Risk Anal. 1988. PMID: 3244858
-
Incorporation of the glutathione conjugation pathway in an updated physiologically-based pharmacokinetic model for perchloroethylene in mice.Toxicol Appl Pharmacol. 2018 Aug 1;352:142-152. doi: 10.1016/j.taap.2018.05.033. Epub 2018 May 29. Toxicol Appl Pharmacol. 2018. PMID: 29857080 Free PMC article.
-
Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene.Crit Rev Toxicol. 2005 Jun;35(5):413-33. doi: 10.1080/10408440590931994. Crit Rev Toxicol. 2005. PMID: 16097137 Review.
-
Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(1):31-53. doi: 10.1081/GNC-200051856. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005. PMID: 16291521 Review.
Cited by
-
Whole body pharmacokinetic models.Clin Pharmacokinet. 2003;42(10):883-908. doi: 10.2165/00003088-200342100-00002. Clin Pharmacokinet. 2003. PMID: 12885263 Review.
-
Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam.J Pharmacokinet Pharmacodyn. 2004 Jun;31(3):185-213. doi: 10.1023/b:jopa.0000039564.35602.78. J Pharmacokinet Pharmacodyn. 2004. PMID: 15518244
-
Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. I. Toluene and m-xylene.Int Arch Occup Environ Health. 1993;64(8):569-80. doi: 10.1007/BF00517703. Int Arch Occup Environ Health. 1993. PMID: 8314616
-
Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.Environ Health Perspect. 1994 Dec;102 Suppl 11(Suppl 11):37-50. doi: 10.1289/ehp.94102s1137. Environ Health Perspect. 1994. PMID: 7737040 Free PMC article. Review.
-
Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment.Environ Health Perspect. 2000 May;108 Suppl 2(Suppl 2):283-305. doi: 10.1289/ehp.00108s2283. Environ Health Perspect. 2000. PMID: 10807559 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources